Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Arcus Biosciences Inc (NYSE: RCUS) closed at $8.12 in the last session, down -9.17% from day before closing price of $8.94. In other words, the price has decreased by -$9.17 from its previous closing price. On the day, 0.92 million shares were traded.
Ratios:
We take a closer look at RCUS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 27 ’25 when KANEKO YASUNORI bought 20,000 shares for $10.06 per share. The transaction valued at 201,200 led to the insider holds 28,400 shares of the business.
ROSEN TERRY J bought 19,800 shares of RCUS for $201,465 on Feb 27 ’25. The Chief Executive Officer now owns 2,554,160 shares after completing the transaction at $10.18 per share. On Feb 18 ’25, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 1,363,636 shares for $11.00 each. As a result, the insider paid 14,999,996 and bolstered with 31,424,760 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.33 while its Price-to-Book (P/B) ratio in mrq is 1.54.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $18.98, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is -6.39%, while the 200-Day Moving Average is calculated to be -41.11%.
Shares Statistics:
A total of 92.20M shares are outstanding, with a floating share count of 64.92M. Insiders hold about 38.68% of the company’s shares, while institutions hold 50.65% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 4.0 analysts. The consensus estimate for the next quarter is -$1.02, with high estimates of -$0.9 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$3.56 and -$4.85 for the fiscal current year, implying an average EPS of -$4.01. EPS for the following year is -$4.23, with 5.0 analysts recommending between -$3.23 and -$5.17.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $37.36M. It ranges from a high estimate of $65M to a low estimate of $20M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $39MFor the next quarter, 8 analysts are estimating revenue of $37.36M. There is a high estimate of $65M for the next quarter, whereas the lowest estimate is $20M.
A total of 10 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $263M, while the lowest revenue estimate was $80M, resulting in an average revenue estimate of $154.46M. In the same quarter a year ago, actual revenue was $258MBased on 10 analysts’ estimates, the company’s revenue will be $181.89M in the next fiscal year. The high estimate is $283.67M and the low estimate is $40M.
